Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. The company’s first product, Korlym® (mifepristone) 300 mg Tablets has been approved by the FDA for the control of hyperglycemia associated with Cushing syndrome. www.corcept.com